Product
NovoRapid
Aliases
NovoRapid®;HR011408 injection, NovoRapid®; HR011408 injection Placebo
3 clinical trials
3 indications
Indication
Diabetes MellitusIndication
Type 2Indication
DiabetesClinical trial
A Single Center, Randomized, Double-Blind, 2-period, 2-sequence Crossover Designed Study to Evaluate the Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy SubjectStatus: Completed, Estimated PCD: 2023-10-26
Clinical trial
A Phase 1, Single Centre, Single Dose, Randomised, Double-blind, Two-way Crossover, Glucose Clamp Study Investigating the Pharmacodynamics, Pharmacokinetics, and Safety of Ultra-rapid-acting Concentrated Insulin Aspart AT278 in Comparison to Standard Insulin Aspart NovoRapid® With an Additional Open Comparison to Humulin® R U-500 in Participants With Type 2 Diabetes.Status: Completed, Estimated PCD: 2024-01-18
Clinical trial
Comparing Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Subjects With Diabetics- A Randomized, Double-Blind, Three-cycle Crossover Phase I Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2024-07-01